Pfizer Inc. (NYSE:PFE) will release earnings results for its fourth quarter, before the opening bell on Tuesday, Feb. 3.
Analysts expect the New York-based company to report quarterly earnings at 57 cents per share, down from 63 cents per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.83 billion, versus $17.76 billion a year earlier, according to data from Benzinga Pro.
On Jan. 20, Novavax, Inc. (NASDAQ:NVAX) announced it entered into a license agreement with Pfizer for use of its Matrix-M adjuvant.
Pfizer shares gained 1.4% to close at $26.44 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Cantor Fitzgerald analyst Carter Gould maintained a Neutral rating and raised the price target from $24 to $27 on Jan. 27, 2026. This analyst has an accuracy rate of 64%.
- UBS analyst Michael Yee maintained the stock with a Neutral rating with a price target of $25 on Jan. 7, 2026. This analyst has an accuracy rate of 62%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and cut the price target from $28 to $27 on Dec. 17, 2025. This analyst has an accuracy rate of 73%.
- B of A Securities analyst Jason Gerberry maintained a Neutral rating and lowered the price target from $29 to $28 on Dec. 15, 2025. This analyst has an accuracy rate of 69%.
- Citigroup analyst Geoff Meacham maintained a Neutral rating with a price target of $26 on Dec. 2, 2025. This analyst has an accuracy rate of 72%.
Considering buying PFE stock? Here’s what analysts think:
Photo via Shutterstock
Recent Comments